I'm not sure timeline comparisons will be all that useful, as DNDN was then first to develop this type of cancer treatment, so it took the market a long time to realise the full value of DNDN. But now that DNDN has paved a way for others with a similar cancer treatment methodology to follow, I think the market is beginning to factor in value to PRR at an earlier stage in product development than was the case with DNDN.
In short, I think we are seeing a re-rating in process, and the recent SP run has a while to go yet before we get to a new base.
I'm not a scientist and this is just my laymans understanding of the difference between DNDN and PRR. Happy to be corrected.
DYOR, V5
I'm not sure timeline comparisons will be all that useful, as...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 41.5¢ | 39.5¢ | $1.576M | 3.906M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2506 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 8079 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |